Kodiak Sciences Inc KOD

NAS: KOD | ISIN: US50015M1099   30/04/2025
4,360 USD (+4,81%)
(+4,81%)   30/04/2025

27 maart 2025 · Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results · Persbericht

10 maart 2025 · Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy · Persbericht

14 augustus 2024 · Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results · Persbericht

29 mei 2024 · Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences · Persbericht

15 mei 2024 · Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results · Persbericht

14 mei 2024 · Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy · Persbericht

2 mei 2024 · Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform · Persbericht

28 maart 2024 · Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results · Persbericht

26 maart 2024 · Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 · Persbericht

30 januari 2024 · Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting · Persbericht

4 januari 2024 · Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

6 november 2023 · Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission · Persbericht

2 november 2023 · Kodiak Sciences Announces First Time Presentation Of Primary Endpoint Data From Tarcocimab Tedromer Phase 3 Glow Study In Patients With Diabetic Retinopathy At American Academy Of Ophthalmology Annual Meeting · Persbericht

11 oktober 2023 · Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society · Persbericht

8 september 2023 · Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference · Persbericht

7 september 2023 · New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion · Persbericht

14 augustus 2023 · Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

24 juli 2023 · Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program · Persbericht

30 mei 2023 · Kodiak Sciences to Present at Upcoming Investor Conferences · Persbericht

15 mei 2023 · Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights · Persbericht

Mijn selecties